Results 11 to 20 of about 1,013 (109)

Later-Line Treatment with Lorlatinib in ALK- and ROS1-Rearrangement-Positive NSCLC: A Retrospective, Multicenter Analysis

Pharmaceuticals, 2020
In clinical practice, patients with anaplastic lymphoma kinase (ALK)-rearrangement–positive non–small-cell lung cancer commonly receive sequential treatment with ALK tyrosine kinase inhibitors.
Maximilian J. Hochmair, Hannah Fabikan, Oliver Illini, Christoph Weinlinger, Ulrike Setinek, Dagmar Krenbek, Helmut Prosch, Markus Rauter, Michael Schumacher, Ewald Wöll, Romana Wass, Elmar Brehm, Gudrun Absenger, Tatjana Bundalo, Peter Errhalt, Matthias Urban, Arschang Valipour   +16 more
doaj   +2 more sources

Update on Lorlatinib: Role in Reducing the Risk of Disease Progression in ALK-Positive NSCLC [PDF]

Cancer Management and Research, 2022
Karen M Yun, Lyudmila A Bazhenova Department of Hematology-Oncology, Moores Cancer Center at UC San Diego Health, La Jolla, CA, USACorrespondence: Lyudmila A Bazhenova, Department of Hematology-Oncology, Moores Cancer Center at UC San Diego Health, 3855 ...
Yun KM, Bazhenova LA
doaj   +2 more sources

Lorlatinib-specific outcomes by timing of lorlatinib initiation in advanced ALK-positive non-small cell lung cancer: A retrospective cohort study

Therapeutic Advances in Medical Oncology
Background The phase III CROWN study established lorlatinib as a standard first-line therapy for advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC).
Ruiqi Song, Xinyue Li, Na Han, Dujiang Liu, Yanjun Xu   +4 more
doaj   +2 more sources

Olanzapine enabled rechallenge after lorlatinib‐induced psychosis: A case report [PDF]

PCN Reports
Background Lorlatinib is a third‐generation tyrosine kinase inhibitor for anaplastic lymphoma kinase (ALK)‐positive non‐small cell lung cancer (NSCLC).
Akiyoshi Yokode, Masaki Fujiwara, Yuko Nakamura, Kadoaki Ohashi, Shinji Sakamoto, Manabu Takaki   +5 more
doaj   +2 more sources

Successful Lorlatinib Rechallenge After Severe Drug-Induced Psychosis in ALK-Positive Metastatic NSCLC: A Case Report

JTO Clinical and Research Reports
Neurocognitive adverse events (NAEs) have been reported in up to 60% of patients on lorlatinib, a potent central nervous system–active ALK inhibitor. Manifestations may include psychotic, mood, speech, and cognitive symptoms.
Alexius John, MBBS, FRACP, Joanna Vick, BSc, NMP, Sarah Sarker, BSc, PGDip, Elizabeth Middleton, BN, Elizabeth Cartwright, MD, MRCP, Thubeena Manickavasagar, MD, MRCP, David McMahon, MB, BCh, BAO, MRCP, Nadza Tokaca, BMBCh, MRCP, Sanjay Popat, PhD, FRCP   +8 more
doaj   +3 more sources

Alectinib and lorlatinib function by modulating EMT-related proteins and MMPs in NSCLC metastasis [PDF]

Biomolecules & Biomedicine, 2021
Most advanced non-small cell lung cancer (NSCLC) patients are accompanied by brain metastasis which is the major cause of increased mortality. The fusion rearrangement of anaplastic lymphoma kinase (ALK) gene is an important feature of brain metastasis ...
Xu Feng, En-Shi Xu
doaj   +2 more sources

Post-marketing safety of lorlatinib: a real-world study based on the FDA adverse event reporting system [PDF]

Frontiers in Pharmacology
BackgroundLorlatinib displays marked systemic and intracranial efficacy against anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer (NSCLC). We aimed to establish the safety profile of lorlatinib based on the Food and Drug Administration
Huqun Li, Chongshu Wang, Cuilian Guo
doaj   +2 more sources

LTK mutations responsible for resistance to lorlatinib in non-small cell lung cancer harboring CLIP1-LTK fusion

Communications Biology
The CLIP1-LTK fusion was recently discovered as a novel oncogenic driver in non-small cell lung cancer (NSCLC). Lorlatinib, a third-generation ALK inhibitor, exhibited a dramatic clinical response in a NSCLC patient harboring CLIP1-LTK fusion.
Shunta Mori, Hiroki Izumi, Mitsugu Araki, Jie Liu, Yu Tanaka, Yosuke Kagawa, Yukari Sagae, Biao Ma, Yuta Isaka, Yoko Sasakura, Shogo Kumagai, Yuta Sakae, Kosuke Tanaka, Yuji Shibata, Hibiki Udagawa, Shingo Matsumoto, Kiyotaka Yoh, Yasushi Okuno, Koichi Goto, Susumu S. Kobayashi   +19 more
doaj   +2 more sources

Case report: ATIC-ALK fusion in infant-type hemispheric glioma and response to lorlatinib [PDF]

Frontiers in Oncology, 2023
IntroductionInfant type hemispheric gliomas are a rare tumor with unique molecular characteristics. In many cases these harbor mutations in receptor tyrosine kinase pathways and respond to targeted therapy.
Shubin W. Shahab, Shubin W. Shahab, Matthew Schniederjan, Matthew Schniederjan, Jose Velazquez Vega, Jose Velazquez Vega, Stephen Little, Andrew Reisner, Andrew Reisner, Andrew Reisner, Tobey MacDonald, Tobey MacDonald, Tobey MacDonald, Dolly Aguilera, Dolly Aguilera   +14 more
doaj   +2 more sources

Acquired G2032R Resistance Mutation in ROS1 to Lorlatinib Therapy Detected with Liquid Biopsy

Current Oncology, 2022
Lorlatinib, a third-generation anaplastic lymphoma kinase (ALK)/receptor tyrosine kinase inhibitor (ROS1), demonstrated efficacy in ROS1 positive (ROS1+) non-small cell lung cancer (NSCLC), although approval is currently limited to the treatment of ALK ...
Balázs Jóri, Markus Falk, Iris Hövel, Peggy Weist, Markus Tiemann, Lukas C. Heukamp, Frank Griesinger   +6 more
doaj   +2 more sources